Pseudoginsenoside F11

Pseudoginsenoside F11 (Ginsenoside A1), a component of Panax quinquefolium (American ginseng), has been demonstrated to antagonize the learning and memory deficits induced by scopolamine, morphine and methamphetamine in mice.

Product information

CAS Number: 69884-00-0

Molecular Weight: 801.01

Formula: C42H72O14

Chemical Name: (2S, 3R, 4R, 5R, 6S)-2-(((2R, 3R, 4S, 5S, 6R)-2-(((3S, 5R, 6S, 8R, 9R, 10R, 12R, 13R, 14R, 17S)-3, 12-dihydroxy-17-((2S, 5R)-5-(2-hydroxypropan-2-yl)-2-methyltetrahydrofuran-2-yl)-4, 4, 8, 10, 14-pentamethylhexadecahydro-1H-cyclopenta[a]phenanthren-6-yl)oxy)-4, 5-dihydroxy-6-(hydroxymethyl)tetrahydro-2H-pyran-3-yl)oxy)-6-methyltetrahydro-2H-pyran-3, 4, 5-triol

Smiles: C[C@@H]1O[C@@H](O[C@H]2[C@H](O[C@H]3C[C@]4(C)[C@H](C[C@@H](O)[C@@H]5[C@H](CC[C@@]45C)[C@]4(C)CC[C@@H](O4)C(C)(C)O)[C@@]4(C)CC[C@H](O)C(C)(C)[C@@H]43)O[C@H](CO)[C@@H](O)[C@@H]2O)[C@H](O)[C@H](O)[C@H]1O

InChiKey: JBGYSAVRIDZNKA-NKECSCAMSA-N

InChi: InChI=1S/C42H72O14/c1-19-28(46)30(48)32(50)35(52-19)55-33-31(49)29(47)23(18-43)54-36(33)53-22-17-41(8)24(39(6)13-11-25(45)37(2,3)34(22)39)16-21(44)27-20(10-14-40(27,41)7)42(9)15-12-26(56-42)38(4,5)51/h19-36,43-51H,10-18H2,1-9H3/t19-,20-,21+,22-,23+,24+,25-,26+,27-,28-,29+,30+,31-,32+,33+,34-,35-,36+,39+,40+,41+,42-/m0/s1

Technical Data

Appearance: Solid Power

Purity: ≥98% (or refer to the Certificate of Analysis)

Solubility: DMSO : 100 mg/mL (124.84 mM; Need ultrasonic). H2O : 0.67 mg/mL (0.84 mM; Need ultrasonic).

Shipping Condition: Shipped under ambient temperature as non-hazardous chemical or refer to Certificate of Analysis

Storage Condition: Dry, dark and -20 ^oC for 1 year or refer to the Certificate of Analysis.

Shelf Life: ≥12 months if stored properly.

Stock Solution Storage: 0 - 4 ^oC for 1 month or refer to the Certificate of Analysis.

Drug Formulation: To be determined

HS Tariff Code: 382200

How to use

In Vitro:

Biochemical experiments revealed that Pseudoginsenoside F11 (Ginsenoside A1) could inhibit diprenorphine (DIP) binding with an IC50 of 6.1 μM and reduced the binding potency of morphine in Chinese hamster ovary (CHO)-μ cells.

In Vivo:

One in vivo model of cisplatin-induced acute renal failure was performed. The results showed that pretreatment with Pseudoginsenoside Pseudoginsenoside F11 (Ginsenoside A1) reduced cisplatin-elevated blood urea nitrogen and creatinine levels, as well as ameliorated the histophathological damage . We tested the effects of Pseudoginsenoside Pseudoginsenoside F11 (Ginsenoside A1) on morphine-induced development of behavioral sensitization and alterations in glutamate levels in the medial prefrontal cortex (mPFC) in freely moving mice by using in vivo microdialysis. As the results shown, Pseudoginsenoside Pseudoginsenoside F11 (Ginsenoside A1) antagonized the development of behavioral sensitization and decrease of glutamate in the mPFC induced by morphine.

Products are for research use only. Not for human use.